ILF3

Across TCGA pan-cancer cohorts, ILF3 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated ILF3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ILF3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ILF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and CESC are the cancer types where ILF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.155	0.542	.001	36	view →
UCEC	OS	Median	II,III,IV	0.948	0.317	.007	32	view →
CESC	DFS	Median	III,IV	0.091	0.728	<.001	30	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	6	view →
BRCA	OS	Median	All	0.170	0.579	.047	4	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
COAD	DFS	Median	II,III,IV	0.438	0.693	.037	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

ILF3–OV (DFS)

Open the OV breakdown →